3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Renal Cell
23
Glioblastoma
13
Lymphoma, Mantle-Cell
10
Endometrial Neoplasms
10
Prostatic Neoplasms
9
Neoplasms
9
Breast Neoplasms
9
Brain Neoplasms
9
Neoplasm Metastasis
8
Kidney Neoplasms
8
Gliosarcoma
8
Melanoma
7
Sarcoma
6
Lymphoma, Non-Hodgkin
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Ovarian Neoplasms
5
Oligodendroglioma
5
Multiple Myeloma
5
Lymphoma, Follicular
5
Lymphoma
5
Glioma
5
Astrocytoma
5
Waldenstrom Macroglobulinemia
4
Uterine Cervical Neoplasms
4
Lymphoma, B-Cell, Marginal Zone
4
Fallopian Tube Neoplasms
4
Central Nervous System Neoplasms
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Rhabdomyosarcoma
3
Osteosarcoma
3
Interventions
temsirolimus
1
copanlisib
1
cabozantinib
1
Therapeutics
1
Taxes
1
Radiation, Ionizing
1
Paclitaxel
1
Dasatinib
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Endometrioid
×
temsirolimus
×
Clear all
NCT02093598
2020-11-27
POEM
MedSIR
Phase 2
Completed
10 enrolled